Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Primary Vitreoretinal Lymphoma: later-stage trial registry

1 of 1 indexed Primary Vitreoretinal Lymphoma trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Primary Vitreoretinal Lymphoma: 1 US clinical trial tracked, 1 recruiting.

Primary Vitreoretinal Lymphoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Aldeyra Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition primary-vitreoretinal-lymphoma

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Primary Vitreoretinal Ly (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Primary Vitreoretinal Lymphoma

Primary Vitreoretinal Lymphoma lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Primary Vitreoretinal Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Primary Vitreoretinal Lymphoma is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on Primary Vitreoretinal Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Monthly ADX-2191 injection Drug
1 trials
ICM ADX-2191 injection Drug
1 trials

US sites by state

Facility locations filed on Primary Vitreoretinal Lymphoma trials. A trial with sites in several states counts in each.

Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Primary Vitreoretinal Lymphoma page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Primary Vitreoretinal Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Aldeyra Therapeutics sponsors the most Primary Vitreoretinal Lymphoma trials on record, review their full trial history before evaluating a specific study. See Aldeyra Therapeutics's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Vitreoretinal Lymphoma condition card totals 1 registered trials; most-linked intervention Monthly ADX-2191 injection; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.